Home / The Results / Our Portfolio Companies
Our Portfolio Companies

A Track Record of Success
The Foundry is the premier medical device company incubator for inventors to rapidly transform their concepts into companies by providing a combination of  an experienced, multi-disciplinary leadership team, state-of-the-art facility and extensive funding network. The Foundry team is made up of veteran medical device entrepreneurs and investors with direct first-hand experience—and success—developing world class medical device companies.

Since its inception in 1998, The Foundry has founded and financed over ten medical device companies. These businesses have generated in excess of $2 billion of value for their founders and investors and employ more than 500 people today, further establishing our solid track record of success.

For more detailed information on any of The Foundry's portfolio companies, including career opportunities and press releases, please contact the companies directly.

Ardian, Inc.
Founded in 2003, Ardian is developing the Symplicity® Catheter System,™ a novel treatment for hypertension and related conditions. In 2011, Ardian was acquired by Medtronic, Inc.


Cabochon Aesthetics
Founded in 2005, Cabochon Aesthetics is dedicated to developing effective scientific solutions for aesthetic procedures.

In 2014, Cabochon was acquired by Ulthera, Inc.


Concentric Concentric Medical, Inc.  
Founded in 1999, Concentric Medical is a medical device company committed to opening the pathway to stroke treatment. In 2011, Concentric was acquired by Stryker, Inc.


Cotera Cotera
Founded in 2011, Cotera is developing implantable devices for treatment of knee osteoarthritis.


Emphasys Medical, Inc.
Founded in 2000, Emphasys Medical develops minimally invasive therapies to benefit patients with Chronic Obstructive Pulmonary Disease. After a successful clinical trial demonstrating the benefits of its endobronchial valves did not lead to FDA approval, Emphasys was sold to Pulmonx, Inc. in 2009.


Evalve, Inc.
Founded in 1999, Evalve designs, develops, manufactures and markets innovative devices to enable percutaneous repair of mitral heart valves. In 2009, Evalve was acquired by Abbott.


FIRE1 logo FIRE1
Founded in 2013, FIRE1 is developing a novel medical device and is based in Dublin, Ireland.


First to File, Inc.
Founded in 2000, First to File is dedicated to revolutionizing the intellectual property process. In 2002, First to File was acquired by MarkMonitor to form an integrated suite of intellectual property tools.


ForSight Labs, LLC
ForSight Labs is an ophthalmic company incubator, co-founded in 2005 by Dr. Eugene de Juan, Jr. and The Foundry, driven to significantly improve the quality of life of millions facing vision impairment.


ForSight VISION2
ForSight Newco II (Vision2) was founded in 2006 and is developing a proprietary ocular punctal plug drug delivery system. Vision2 was acquired by and became a wholly owned subsidiary of QLT, Inc., in 2007.


Foundry Therapeutics 1, Inc.
Founded in 2016, Foundry Therapeutics 1 is developing innovative, opioid-free solutions for treating postoperative pain.


Half Moon Medical
Founded in 2017, Half Moon Medical is working to improve and extend patient lives by pioneering a novel transcatheter treatment paradigm to significantly reduce mitral regurgitation.


Founded in 2008, Nuvaira is developing devices for treating lung diseases.


Miramar Labs
Founded in 2006, Miramar Labs is bringing new technologies to the field of lifestyle medicine. The first clinical market Miramar is addressing is hyperhidrosis—the debilitating problem of excess sweating.


Satiety, Inc.
Founded in 2001, Satiety develops minimally invasive devices to treat obesity and certain other gastrointestinal conditions. Satiety completed a successful randomized trial demonstrating weight loss. In 2011, the technology was sold to a major medical device company.


Transcend Medical, Inc.
Founded in 2005, Transcend Medical is focused on developing a minimally invasive device for the treatment of glaucoma.
In 2016, Transcend was acquired by Alcon.


Twelve, Inc.
Founded in 2009, Twelve is focused on transforming mitral valve replacement. In 2015, Twelve was acquired by Medtronic, Inc.

Xtent, Inc. NASDAQ: XTNT
Founded in 2002, Xtent developed customizable drug-eluting stent systems for the treatment of coronary artery disease.  Xtent had a successful IPO in 2007. In 2009, the technology was sold to JW Medical, Inc., which continues development.
  © 2001-2019 The Foundry, LLC. All rights reserved. The Foundry is a registered trademark of The Foundry, LLC.